Generation and characterization of a monoclonal antibody that recognizes an activation antigen expressed by a majority of adherent lymphokine-activated killer cells

被引:2
作者
Chan, CS [1 ]
Kane, KP [1 ]
机构
[1] Univ Alberta, Dept Med Microbiol & Immunol, Fac Med, Edmonton, AB T6G 2S2, Canada
来源
HYBRIDOMA | 2000年 / 19卷 / 01期
关键词
D O I
10.1089/027245700315798
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
In an attempt to generate murine natural killer (NK) cell-specific monoclonal antibodies (MAbs) by immunizing Balb/c mice with C57BL/6 (B6) A-LAKs, we have isolated a hybridoma, CS/NicT.2, which secretes an IgM that recognizes a majority of B6 and B6 Rag-1(-/-) A-LAKs. The CS/NicT.2 antigen is highly expressed by A-LAKs, but only at extremely low levels on resting splenocytes, suggesting that its expression is tightly associated with IL-2 activation, Among the cell lines examined, only CTLL-2 expresses the CS/NicT.2 antigen at relatively high levels. A low level of CS/NicT.2 staining is also detected on resting allo-specific cytotoxic T lymphocytes (CTL) clones, AB.1 and C11. In addition, a similar low level of CS/NicT.2 staining is detected on the T-helper cell line HT-2, The CS/NicT.2 antigen is upregulated by ionomycin but not by phorbol 12-myristate 13-acetate (PMA). For the CTL clones examined, CS/NicT.2 staining is also dramatically increased by anti-TCRbeta or anti-CD3(epsilon) stimulation, Protease treatments of CTLL-2 show that this antigen is proteinase K sensitive, but relatively resistant to trypsin digestion. Furthermore, the CS/NicT.2 antigen exhibits a relatively fast turnover rate as assessed by proteinase K and cycloheximide treatments of CTLL-2, suggesting that the CS/NicT.2 antigen may have a short half-life on the cell surface.
引用
收藏
页码:49 / 61
页数:13
相关论文
共 28 条
[1]   CHARACTERIZATION OF THE LYMPHOCYTE-ACTIVATION GENE 3-ENCODED PROTEIN - A NEW LIGAND FOR HUMAN-LEUKOCYTE ANTIGEN CLASS-II ANTIGENS [J].
BAIXERAS, E ;
HUARD, B ;
MIOSSEC, C ;
JITSUKAWA, S ;
MARTIN, M ;
HERCEND, T ;
AUFFRAY, C ;
TRIEBEL, F ;
PIATIERTONNEAU, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (02) :327-337
[2]  
Berg NN, 1998, J IMMUNOL, V161, P2919
[3]  
BIX M, 1995, J IMMUNOL, V155, P1020
[4]   The murine nonclassical class I major histocompatibility complex-like CD1.1 molecule protects target cells from lymphokine-activated killer cell cytolysis [J].
Chang, CS ;
Brossay, L ;
Kronenberg, M ;
Kane, KP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (03) :483-491
[5]   Generation of a monoclonal antibody that recognizes a polymorphic epitope of C57BL/6 Ly-49G2 [J].
Chang, CS ;
Silver, ET ;
Kane, KP .
HYBRIDOMA, 1999, 18 (05) :423-429
[6]  
DEVRIES JE, 1989, IMMUNOL REV, V109, P119
[7]   A comparison of efficacy and specificity of three NK depleting antibodies [J].
Ehl, S ;
Nuesch, R ;
Tanaka, T ;
Myasaka, M ;
Hengartner, H ;
Zinkernagel, R .
JOURNAL OF IMMUNOLOGICAL METHODS, 1996, 199 (02) :149-153
[8]  
GARNIWAGNER BA, 1993, J IMMUNOL, V151, P60
[9]   LONG-TERM CULTURE OF TUMOR-SPECIFIC CYTOTOXIC T-CELLS [J].
GILLIS, S ;
SMITH, KA .
NATURE, 1977, 268 (5616) :154-156
[10]   CHARACTERISTICS AND USES OF NATURAL-KILLER CELLS [J].
HERCEND, T ;
SCHMIDT, RE .
IMMUNOLOGY TODAY, 1988, 9 (10) :291-293